174 related articles for article (PubMed ID: 26456843)
1. Reply to "Statin treatment for non-alcoholic steatohepatitis".
Dongiovanni P; Pihlajamaki J; Romeo S; Valenti L
J Hepatol; 2016 Jan; 64(1):242-3. PubMed ID: 26456843
[No Abstract] [Full Text] [Related]
2. Statins and non-alcoholic steatohepatitis.
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
J Hepatol; 2016 Jan; 64(1):241-2. PubMed ID: 26456845
[No Abstract] [Full Text] [Related]
3. Statin use and non-alcoholic steatohepatitis in at risk individuals.
Dongiovanni P; Petta S; Mannisto V; Mancina RM; Pipitone R; Karja V; Maggioni M; Kakela P; Wiklund O; Mozzi E; Grimaudo S; Kaminska D; Rametta R; Craxi A; Fargion S; Nobili V; Romeo S; Pihlajamaki J; Valenti L
J Hepatol; 2015 Sep; 63(3):705-12. PubMed ID: 25980762
[TBL] [Abstract][Full Text] [Related]
4. Reply to "statins and non-alcoholic steatohepatitis".
Barb D; Cusi K
Metabolism; 2017 Jan; 66():e3-e5. PubMed ID: 27865560
[No Abstract] [Full Text] [Related]
5. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
6. [Steatosis and non-alcoholic steatohepatitis].
Marín-López ER; Marín-Rentería NM
Rev Gastroenterol Mex; 2013 Aug; 78 Suppl 1():96-7. PubMed ID: 24041073
[No Abstract] [Full Text] [Related]
7. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
Tzefos M; Olin JL
J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Chalasani N; Younossi Z; Lavine JE; Diehl AM; Brunt EM; Cusi K; Charlton M; Sanyal AJ; ; ;
Am J Gastroenterol; 2012 Jun; 107(6):811-26. PubMed ID: 22641309
[No Abstract] [Full Text] [Related]
9. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease.
Pastori D; Polimeni L; Baratta F; Pani A; Del Ben M; Angelico F
Dig Liver Dis; 2015 Jan; 47(1):4-11. PubMed ID: 25224698
[TBL] [Abstract][Full Text] [Related]
10. Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?
Tessier CM; Polyzos SA; Athyros VG; Mantzoros CS
Metabolism; 2021 Aug; 121():154796. PubMed ID: 33989632
[No Abstract] [Full Text] [Related]
11. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
Athyros VG; Katsiki N; Mikhailidis DP
Curr Vasc Pharmacol; 2016; 14(4):313-5. PubMed ID: 27173023
[No Abstract] [Full Text] [Related]
12. Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
Athyros VG; Katsiki N; Mikhailidis DP
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101842. PubMed ID: 34920141
[No Abstract] [Full Text] [Related]
13. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Younossi ZM; Reyes MJ; Mishra A; Mehta R; Henry L
Aliment Pharmacol Ther; 2014 Jan; 39(1):3-14. PubMed ID: 24206433
[TBL] [Abstract][Full Text] [Related]
14. Statins and non-alcoholic steatohepatitis.
Athyros VG; Katsiki N; Mikhailidis DP
Metabolism; 2017 Jan; 66():e1-e2. PubMed ID: 27836113
[No Abstract] [Full Text] [Related]
15. Response letter: Statins and non-alcoholic steatohepatitis.
Athyros VG; Katsiki N; Mikhailidis DP
Metabolism; 2017 Jan; 66():e6. PubMed ID: 27842716
[No Abstract] [Full Text] [Related]
16. Alcoholic liver disease: Mucosal microbes exacerbate experimental alcoholic steatohepatitis.
Ray K
Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):121. PubMed ID: 26882878
[No Abstract] [Full Text] [Related]
17. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
[TBL] [Abstract][Full Text] [Related]
18. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
Caldwell S
Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
[TBL] [Abstract][Full Text] [Related]
19. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis].
Wiegand J; Mössner J; Tillmann HL
Internist (Berl); 2007 Feb; 48(2):154-63. PubMed ID: 17226007
[TBL] [Abstract][Full Text] [Related]
20. Altered intestinal microbiota as a major driving force in alcoholic steatohepatitis.
Tilg H; Mathurin P
Gut; 2016 May; 65(5):728-9. PubMed ID: 26786686
[No Abstract] [Full Text] [Related]
[Next] [New Search]
